Tags

Type your tag names separated by a space and hit enter

Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis.

Abstract

CONTEXT

Circulating levels of 25-hydroxyvitamin D [25(OH)D] may affect the prognosis of cancer patients; however, the epidemiological results are not consistent.

OBJECTIVE

To perform a meta-analysis of all published studies to assess the associations of circulating 25(OH)D levels measured at or near the time of diagnosis and outcomes for cancer patients.

DATA SOURCES

Searches of the PubMed and MEDLINE databases were performed and updated to December 2013.

STUDY SELECTION

Studies reporting an association between circulating 25(OH)D levels at or near the time of diagnosis and outcomes for the patients were included.

DATA EXTRACTION

Data extraction was performed independently by two authors, and conflicts were resolved by a third investigator.

DATA SYNTHESIS

Included in the meta-analysis were 25 studies with 17 332 cases. Significant associations between circulating 25(OH)D levels at or near the time of diagnosis and the outcomes for cancer patients were found. The pooled hazard ratio for the highest vs the lowest quartile of circulating 25(OH)D levels was 0.55 (95% confidence interval [CI] = 0.33-0.91) for overall survival of colorectal cancer patients, 0.63 (95% CI = 0.51-0.77) for breast cancer patients, and 0.48 (95% CI = 0.36-0.64) for lymphoma patients. Higher 25(OH)D levels were significantly associated with reduced cancer-specific mortality for patients with colorectal cancer (P = .005) and lymphoma (P < .001) and improved disease-free survival for patients with breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D levels conferred a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival of the cancer patients.

CONCLUSIONS

The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Key Laboratory of Food Safety Research (M.L., P.C., J.L., R.C., D.X., H.W.), Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China; Key Laboratory of Food Safety Risk Assessment (D.X., H.W.), Ministry of Health, Beijing 100021, China; and School of Life Science and Technology (D.X., H.W.), Shanghai Tech University, Shanghai, 200031, China.

    , , , ,

    Source

    MeSH

    Case-Control Studies
    Cohort Studies
    Female
    Humans
    Male
    Neoplasms
    Prognosis
    Vitamin D

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Research Support, Non-U.S. Gov't
    Review
    Systematic Review

    Language

    eng

    PubMed ID

    24780061

    Citation

    Li, Mian, et al. "Review: the Impacts of Circulating 25-hydroxyvitamin D Levels On Cancer Patient Outcomes: a Systematic Review and Meta-analysis." The Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 7, 2014, pp. 2327-36.
    Li M, Chen P, Li J, et al. Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99(7):2327-36.
    Li, M., Chen, P., Li, J., Chu, R., Xie, D., & Wang, H. (2014). Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. The Journal of Clinical Endocrinology and Metabolism, 99(7), pp. 2327-36. doi:10.1210/jc.2013-4320.
    Li M, et al. Review: the Impacts of Circulating 25-hydroxyvitamin D Levels On Cancer Patient Outcomes: a Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2014;99(7):2327-36. PubMed PMID: 24780061.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. AU - Li,Mian, AU - Chen,Peizhan, AU - Li,Jingquan, AU - Chu,Ruiai, AU - Xie,Dong, AU - Wang,Hui, Y1 - 2014/04/29/ PY - 2014/5/1/entrez PY - 2014/5/2/pubmed PY - 2014/9/30/medline SP - 2327 EP - 36 JF - The Journal of clinical endocrinology and metabolism JO - J. Clin. Endocrinol. Metab. VL - 99 IS - 7 N2 - CONTEXT: Circulating levels of 25-hydroxyvitamin D [25(OH)D] may affect the prognosis of cancer patients; however, the epidemiological results are not consistent. OBJECTIVE: To perform a meta-analysis of all published studies to assess the associations of circulating 25(OH)D levels measured at or near the time of diagnosis and outcomes for cancer patients. DATA SOURCES: Searches of the PubMed and MEDLINE databases were performed and updated to December 2013. STUDY SELECTION: Studies reporting an association between circulating 25(OH)D levels at or near the time of diagnosis and outcomes for the patients were included. DATA EXTRACTION: Data extraction was performed independently by two authors, and conflicts were resolved by a third investigator. DATA SYNTHESIS: Included in the meta-analysis were 25 studies with 17 332 cases. Significant associations between circulating 25(OH)D levels at or near the time of diagnosis and the outcomes for cancer patients were found. The pooled hazard ratio for the highest vs the lowest quartile of circulating 25(OH)D levels was 0.55 (95% confidence interval [CI] = 0.33-0.91) for overall survival of colorectal cancer patients, 0.63 (95% CI = 0.51-0.77) for breast cancer patients, and 0.48 (95% CI = 0.36-0.64) for lymphoma patients. Higher 25(OH)D levels were significantly associated with reduced cancer-specific mortality for patients with colorectal cancer (P = .005) and lymphoma (P < .001) and improved disease-free survival for patients with breast cancer (P < .001) or lymphoma (P < .05). A 10-nmol/L increment in circulating 25(OH)D levels conferred a hazard ratio of 0.96 (95% CI = 0.95-0.97) for overall survival of the cancer patients. CONCLUSIONS: The results indicate that cancer patients with higher circulating 25(OH)D levels at or near the time of diagnosis have better outcomes. SN - 1945-7197 UR - https://www.unboundmedicine.com/medline/citation/24780061/full_citation L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jc.2013-4320 DB - PRIME DP - Unbound Medicine ER -